Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration.

Details

Ressource 1Download: serval:BIB_86D413480367.P001 (223.43 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_86D413480367
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration.
Journal
Graefe's Archive For Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Author(s)
Mantel I., Deli A., Iglesias K., Ambresin A.
ISSN
1435-702X (Electronic)
ISSN-L
0721-832X
Publication state
Published
Issued date
2013
Volume
251
Number
3
Pages
697-704
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
PURPOSE: To investigate the rhythm and predictability of the need for retreatment with intravitreal injections of ranibizumab for neovascular age-related macular degeneration (nAMD).
METHODS: This prospective study enrolled 39 patients with treatment-naïve nAMD. After three loading doses of intravitreal ranibizumab, patients underwent an intensified follow-up for 12 months (initially weekly, then with stepwise increases to every 2 weeks and to monthly after each injection). Patients were retreated on an as-needed basis if any fluid or increased central retinal thickness (CRT) (>50 μm) was found on spectral domain optical coherence tomography (OCT). Statistical analysis included patients who received at least two retreatments (five injections).
RESULTS: A mean of 7.5 injections (range 0-12) were given between months 3 and 15. The mean visual acuity increased by 13.1 and 12.6 ETDRS letters at months 12 and 15 respectively. Two or more injection-retreatment intervals were found in 31 patients. The variability of their intra-individual intervals up to 14 weeks was small (SD 0-2.13 weeks), revealing a high regularity of the retreatment rhythm. The SD was correlated with the mean interval duration (r = 0.89, p < 0.001). The first interval was a good predictor of the following intervals (regression coefficient =0.81). One retreatment criterion was stable in 97 % of patients (cysts or subretinal fluid).
CONCLUSION: The results of this study demonstrate a high intra-individual predictability of retreatment need with ranibizumab injections for nAMD. These findings may be helpful for developing individualized treatment plans for maintained suppression of disease activity with a minimum of injections and visits.
Pubmed
Web of science
Open Access
Yes
Create date
12/04/2013 17:48
Last modification date
01/10/2019 6:18
Usage data